Apogee Therapeutics, Inc. Cash and Restricted Cash
Apogee Therapeutics, Inc. (APGE) had Cash and Restricted Cash of $105.57 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $105.57M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $451.80M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $131.55M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $107.91M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $105.57M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $451.80M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $131.55M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $107.91M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $124.49M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $107.21M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $142.08M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $119.07M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $307.59M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $485.75M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $118.61M 10-K · filed 2026-03-02 |
| 2023-09-30 | $188.27M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $125.07M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $141.33M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $151.89M 10-K · filed 2026-03-02 |
| 2022-09-30 | $2.58M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $4.97M 10-Q · filed 2023-08-28 |